The FDA-approved mTORC1 inhibitor everolimus increases progression-free survival when combined with the non-steroidal aromatase inhibitor exemestane for patients with HR(+) and HER2(−) advanced breast cancer [133]. The gene discussed is ERBB2; the disease is breast carcinoma.